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HIGHLIGHTS 
 EOP relates to high risk of complications, technique failure and death in PD patients 
 Although some risk factors were examined, no risk score was derived to predict EOP 
 A well-discriminated and calibrated score for EOP has been derived and validated  













Early onset peritonitis (EOP) increases risk of clinical complications in patients initialising 
peritoneal dialysis (PD). This study aimed to develop and validate a risk prediction model 
for EOP among patients initialising PD. 
Methods 
3,772 patients registered with the Henan Peritoneal Dialysis Registry (HPDR) between 
2007-2015 were included. The main outcome, EOP was defined as the incident 
peritonitis occurred within 6 months since the initialisation of PD. Multivariable logistic 
regression modelling was applied to derive the risk score. All accessible clinical 
measurements were screened as potential predictors. Assessment of the developed 
model regarding model discrimination and calibration was performed by C statistics and 
calibration slope, respectively, and validated internally through bootstrapping (1000-fold) 
method to adjust for over-fitting. 
 
Results 
The absolute risk of EOP was 14.5%. Age, cardiac function measurements, serum 
electrolyte test items, lipid profiles, liver function test items, blood urea nitrogen, and 
white cell count were significant predictors of EOP in the final risk score. Good model 
discrimination with C statistics above 0.70 and calibration of agreed observed and 
predicted risks were identified in the model.   
Conclusion 
The prediction model that quantify risks of EOP has been developed and validated. It is 
based on a small number of clinical metabolic measurements that are available for 
patients initialising PD in many developing countries and could serve as the tools to 
screen the population at high risk of EOP. 
 
Keywords: Early-onset peritonitis; Peritoneal dialysis; Prognostic model; Cohort 
 
Introduction 
Technological advances have allowed peritoneal dialysis (PD) to be increasingly applied 
to end-stage renal disease (ESRD) patients, especially in developing countries 1. As a 
common and serious complication of peritoneal dialysis, peritonitis was estimated to be 









persistent peritonitis can result in peritoneal membrane injury, promoting the progress of 
encapsulating peritoneal sclerosis 4,5.  
 
Early-onset peritonitis (EOP) is a clinical term that has been recently widely used in 
emerging studies due to the growing interest as patients with EOP appear to be placed 
at an increased risk of clinical complications, covering technique failure and all-cause 
mortality, when compared to those patients who develop to peritonitis later since their 
initialisation of PD treatment 6,7. The period to define the EOP ranged from 3 months to 2 
years across studies 8,9. Most commonly, the definition of ‘early-onset’ has been 6 
months 2,3,8. 
 
Although several prognostic factors for EOP have been reported in several studies, 
including modifiable risk factors and non-modifiable risk factors 10-12, few risk prediction 
algorithm to predict the individual-level risk of EOP have been derived among patients 
initialising PD. Risk algorithms based on clinical measurements collected by the 
initialisation of PD care could help the identification of patients initialising PD with high 
probability of EOP and provide tailored education program and anti-infection therapies. 
Furthermore, different from patients registered in PD care settings in developed 
countries, among many developing countries like China, validated health records are 
very difficult to be accessible due to restricted primary or secondary care systems which 
are unable to accurately record pre-existing comorbidities and treatments 13,14. Relying 
on patients’ self-reported medical history could be misleading in PD care settings, this 
current study therefore aimed to develop and validate a risk prediction model that can be 









utilising objective routinely recorded clinical measurements potentially to be accessible in 




Registry data the Henan Peritoneal Dialysis Registry (HPDR) were used derive and 
validate the risk prediction model 1.  HPDR is administrated under the auspices of the 
Department of Nephrology, the First Affiliated Hospital of Zhengzhou University which is 
in charge of an independent audit and analysis of medical care for renal disease in the 
province 1,15.  
 
Over the study period, patients’ information was prospectively collected electronically 
from all renal departments across the province 1. All data at the HPDR are subjected to 
an extreme-value detection process which identifies suspicious measurements, which are 
then further examined and corrected where necessary by contacting the nephrological 
department 1. This study was designed as a cohort study, which included all patients 
aged ≥ 18 years (n=3,772) who commenced PD between 2007-2015 and who had at 
least 6-month follow-up after baseline measurement 13.   
 
Ethics approval was granted by the Clinical Research Ethics Committee of the First 
Affiliated Hospital of Zhengzhou University (REF No.: KY-2017-22). Written informed 
consent was obtained from all participants before inclusion. 
 
Defining outcome, predictors, missing data and power calculation 
 
The outcome was defined as recorded EOP, peritonitis within 6-months since the start of 








self-reported comorbidities, and clinical measurements collected by the initialisation of 
PD care were reviewed and screened by 3 clinicians. Prognostic factors consented to be 
clinically relevant by ≥2 clinicians were chosen in the analysis for further evaluation as 
candidate predictors. Logistic regression model with backward elimination, with all 
candidate predictors, was applied to decide the parameters for the final prediction model. 
For prognostic factors included in the final model, our cohort had missing information on 
body mass index (12.36%),  phosphate (16.76%), albumin (15.28%), total protein 
(12.36%), total cholesterol (20.06%), low density lipoprotein (20.17%), fasting glucose 
(12.37%), sodium (3.26%), systolic blood pressure (3.16%), and diastolic blood pressure 
(3.36%). We applied multiple imputation to replace missing values by using a chained 
equation method based on all prognostic factors and outcome to improve the model 
accuracy 16. We generated twenty imputed datasets for missing prognostic factors that 
were then combined across twenty datasets by using Rubin’s rule to derive final model 
estimates 16. With 546 EOP during the first 6 months since the start of PD and 23 
parameters in the final model, a sample size was estimated with 24 final events per 
predictor, higher than the minimum requirement suggested by Peduzzi et al. 17. 
 
Model development and validation 
 
In our study, having an incident episode of peritonitis within the first 6 months of 
initialising PD was treated as a binary outcome measure.  Candidate prognostic factors 
that were not statistically significant were excluded from the backward elimination Logistic 
regression model (P> 0.1 based on change in log likelihood)13. Two-degree fractional 
polynomial terms were used to model non-linear associations between outcomes and 
continuous predictors 18. Fractional polynomial parameters were also re-checked at this 









polynomial term) was decided by the model fitness and performance based on joint by 
parameters19. The risk algorithm is estimated as the log odds from the final model with 
the selected prognostic factors (and polynomials), and the estimated risk (probability) is 
derived from the log odds 20. 
 
We assessed model calibration by plotting the mean predicted risk (probability) against 
the mean observed proportion of EOP by tenth of predicted risk 21. We used the 
concordance statistic (C-statistic) to evaluate model discrimination 20. Model 
discrimination was internally validated by calculating the bootstrap optimism-corrected c-
statistic with 1000 bootstrap replications 13.  
 
To facilitate model utilisation in clinical practice, the logistic regression equations were 
transformed into prognostic score charts 13. The coefficients in the logistic regression 
equation were multiplied by 50 and rounded to the nearest integer to obtain the 
prognostic score per predictor 21. Multiplication by 50 was chosen to ensure that a 
majority of the coefficients were close to be an integer, thereby minimizing the effects of 
rounding. The sum of all prognostic scores reflects patients’ probability of EOP 21. 
 
Stata MP V15.1 (StataCorp, College Station, TX, USA) were used for all statistical 
analyses. Our study was conducted and reported in line with the Transparent Reporting 














546 newly diagnosed EOP episodes since the start of PD were identified from this 
current cohort that incorporates 3,772 patients initialising PD. The characteristics and 
clinical measurements recorded at baseline among patients initialising PD were 
presented in Table-1. 57.8% of patients were male gender.14.8% and 39.9 of patients 
had existing type 2 diabetes and cardiovascular diseases, respectively. The median 
(interquartile range) for age, body mass index, estimated glomerular filtration rate, 
systolic and diastolic blood pressure was 48.0 (37.8 to 59.0) years, 22.6 (20.7 to 24.8) 
kg/m2, 4.9 (3.4 to 7.9) mL/min/1.73m2, 145 (136 to 159)mmHg, and 87 (78 to 86)mmHg, 
respectively.  
Model derivation and performance 
The association between each predictor and EOP was estimated by univariable model 
analysis and presented in Supplemental Table-1. 20 predictors (23 parameters) were 
selected from the 38 candidate predictors by backward elimination and kept in the final 
risk prediction model (Table-2). Age, cardiac function measurements (blood pressure, 
heart rate, ejection fraction), serum electrolyte test items (sodium, potassium, carbon 
dioxide combining power), lipid profiles (total cholesterol, triglyceride, low-density 
lipoprotein, high-density lipoprotein), liver function test items (total protein, alanine 
aminotransferase, aspartate transaminase), blood urea nitrogen, and white cell count 
were predictors remained in the final prediction model. 
 
Our final risk prediction model can discriminate patients initialising PD with and without 
EOP as the optimism-adjusted C statistics was 0.759 (95% confidence interval 0.756 to 









slope was 0.991 (0.973 to 1.009) (Table-3). The agreement between the predicted and 
observed proportion of EOP indicated the good calibration (Figure-1). A real clinical 
example was given in the Table-4 and Supplemental Figure-1 gives interpretation of the 
application of prognostic score charts with graphical illustrations for the developed 






The risk algorithm to predict the individual-level risk of future EOP among patients 
initialising PD has been developed and validated in this present cohort study. Good 
model calibration and good discrimination with C-statistics of greater than 0.70 for the 
model was presented in this study. To our knowledge, this is the first prediction tool for 
predicting EOP among patients initialising PD in prospective cohort data. 
 
The majority of previous studies focused on one or more potential risk (potential causal) 
factors for peritonitis. Few studies have previously derived and reported a multivariable 
prediction model for incident risk of EOP based on clinical measurements routinely 
collected and recorded by the start of PD care. Although the overall performance of the 
prediction model is of the most importance, the direction and magnitude of associations 
between some predictors and outcome always deserve some comments. It should be 
recognised though that those associations are not aimed to be, and cannot be 
interpreted as, any type of causal effect estimations on EOP: they were selected for their 









such associations were conditioned on the start of PD care; each model coefficient was 
adjusted for all other parameters in the prediction model, but the minimally sufficient set 
of covariables should be adjusted for confounding would likely differ for each 24. Bearing 
those concerns in mind, we noted that decreased risk of EOP was found among those 
with higher level metabolic measurements, like triglyceride, total cholesterol and glucose, 
which might include a very small direct causal effect but which otherwise we would 
interpret as reflecting a mixture of a proxy of health status 25, risk of future progression of 
EOP, as patients at low health status (having high measurement of metabolic 
measurements) would more like adhere to standard PD techniques comparing those at 
relatively high health status (having low measurement of metabolic measurements) 26,27. 
Instead of investigating the causal association between cut-offs of prognostic factor 
(predictor) and the outcome in terms of clinical interpretation and application, the aim of 
this study was to make the accurate individual-level risk prediction based on joint-by cut-
offs of predictors in terms of model fitness and performance19. The investigation of 
causal association and further clinical interpretation and utilisation for cut-offs of 
predictors will be made in further studies. 
 
This newly developed risk algorithm could have potentially important application in 
clinical practice by helping direct monitoring, intensive care and timely assessment. This 
algorithm can specifically identify the individual patients who, in terms of current health-
insurance policies and resource, are at higher risk of future EOP and therefore can be 
targeted for tailored care ranging from HR refer to hygiene education program that might 










The hypothetical higher risk individual might, for instance, be targeted for a programme 
of more intensive monitoring and interventions that might prevent such future 
progression of EOP, for example, re-training (covering hand-washing, technique recall, 
protocol adherence, and exit-care) that has been found to significantly delay the onset of 
EOP as studies have demonstrated that PD techniques progressively deteriorate 26. 
 
In the routine PD care, a precise strategy based on individual-level risk of EOP would be 
helpful for clinical decision. Surveillance of patient who initialising of PD care for 
development of EOP is considered as a vital aspect of PD clinical practice quality, 
however, the current guidance of International Society for Peritoneal Dialysis would 
result in intensive intervention being provided to the majority of patients initialising PD 29. 
Although emerging evidence advocates the clinical effectiveness for intensive therapy 
among patients initialising PD, the health burden or over-treatment for all patients 
initialising PD could be another issue that would need aids from individual-level precise 
prediction tool to recognise the high-risk patients.  
 
Among most patients initialising PD, an earlier identification of individual-level patients’ 
risk of upcoming EOP might be helpful to more timely evaluation and discussion of 
proper intensive preventive therapy 28,30. However, it should be cautious against over-
dependence on the current risk prediction model, especially for patients initialising PD 
whose baseline measurements or characteristics indicate they would not be defined as 
potential high-risk patients to accept further intensive therapy although they were 
experiencing some progressive peritonitis. Moreover, although the model developed in 









would be a subgroup of these high-risk individuals with potential risk of recurrent EOP 
even within the 6 months, which suggest further study to develop another new model for 
prediction of recurrent EOP. 
 
There are some advantages in our newly developed risk prediction algorithm in terms of 
its utilisation in most developing countries. The risk algorithm is based in individual-level 
risk developed and validated in a prospective cohort. It is derived from objective 
validated clinical measurements that are routinely tested and recorded for patients 
initialising PD, suggesting that this algorithm can be readily utilised in routine clinical 
practice and is potentially amendable to further validation in many regions and countries 
that practice routine PD. The derivation and validation methods used in this prediction 
model are very close to other that wide-applied prediction models, like QRISK models 
and prediction models developed from CPRD 18,31. The current registration dataset used 
in this study was one of the largest data used to predict EOP among patients initialising 
PD. As the only PD registration dataset in the province, the HPDR incorporated all ESRD 
patients treated by PD in the province, which suggesting a good representativeness. The 
lifetime follow-up since the initialisation of PD was processed for each registered PD 
patient, which suggesting potential low information bias.  
  
This study had several limitations. First, ESRD patients incorporated in this study were 
different from ESRD patients in European studies in terms of age, BMI, comorbidities (as 
Chinese ESRD patients having lower onset-age, lower level of BMI, fewer comorbidities 
and poorer clinical management or treatment). Therefore potential amendments in the 









initialising PD. Second, some traditional risk factors, like smoking and prior health 
information were not accessible in our study. Third, the volume of missing values in 
some predictors (for example, phosphorus and albumin) are relatively high in current 
model. Although the multiple imputation was applied in the model derivation, there still 
might be some information bias impacting the model external application. Fourth, no 
individual-level risk threshold to identify ‘high-risk’ EOP patients was provided in our 
model, as risks of EOP and patients’ benefit would have to be balanced in defining the 
risk threshold, which was not in the scope of this study. Finally, there might be uncertain 
in the application in the external population due to the lack of external validation, the 
need of external validation of our prediction model was highlighted. 
 
Conclusions 
This study has developed and validated a new risk prediction equation to quantify the 
individual-level risk of EOP among patients initialising PD. This risk prediction model has 
the advantage of being based on health records routinely collected in PD care setting, 
making this potentially applicable for automatic risk assessment in electronic medical 
record software. This model can also be used to identify patients at high individual-level 
risk of EOP for further assessments, monitoring and intensive therapy. This prediction 
model is also readily modifiable to further external validation in many developing 
countries that have routinely collected records available for research. Further researches 
are warranted to external validate the model and assess its cost-effectiveness of using 
this risk equation in PD care. 
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Figure-1. Calibration of the prediction model—the observed 6-month probability of 
peritonitis by tenths of model-predicted probability 
 
 
The distributions of actual 0 and 1 values are shown at the bottom and at the 
top of the graph. The ideal 45° line indicates the observed risk equals the predicted risk. 












Table-1. Baseline Characteristics of study cohort. 
 
Candidate Predictors Derivation Cohort 
N 3,772 
Early-onset peritonitis, n (%) 546 (14.5) 
Male Gender, n (%) 2,180 (57.8) 
Primary Glomerular Disease, n (%) 1,833 (48.6) 
Age, years 48.0 (37.8 to 59.0) 
Haemoglobin, g/L 89.0 (75.0 to 103.0) 
Packed cell volume  20.0 (2.8 to 28.0) 
Reticulocyte, %  36.0 (13.1 to 62.8) 
Phosphate, mg/dl 1.8 (1.4 to 2.1) 
Albumin, g/L 33.8 (30.1 to 37.6) 
Total iron binding capacity, μmol/L 44.3 (34.4 to 52.0) 
FeTIBC, mmol/L 26.0 (21.2 to 41.6) 
Creatinine, µmol/L 868.0 (664.0 to 1079.0) 
estimated Glomerular Filtration rate, mL/min/1.73 m2 4.9 (3.4 to 7.9) 
Transferrin, mg/dl 188.0 (104.4 to 388.4) 
Total protein, g/L 57.6 (52.3 to 62.6) 
Prealbumin, mg/L 293.0 (200.0 to 360.0) 
Total Cholesterol, mmol/L 4.4 (3.6 to 5.2) 
Low density lipoprotein, mmol/L 2.5 (2.0 to 3.2) 
High density lipoprotein, mmol/L 1.1 (0.9 to 1.4) 
Alanine aminotransferase, U/L 15.0 (10.0 to 22.0) 
Aspartate transaminase, U/L 17.0 (12.0 to 23.0) 
Fasting glucose, mmol/L 4.8 (4.2 to 5.6) 
carbon dioxide combing power, mmol/L 22.2 (19.1 to 25.7) 
Sodium, mmol/L 140.0 (137.0 to 142.3) 
Potassium, mmol/L 4.3 (3.8 to 4.9) 
C-reaction protein, mg/dl 2.4 (1.0 to 5.3) 
Body mass index, kg/m2 22.6 (20.7 to 24.8) 
Systolic blood pressure, mmHg 145.3 (135.5 to 159.0) 
Diastolic blood pressure, mmHg 87.0 (80.0 to 95.0) 
Erythrocyte sedimentation rate, mm/hr 22 (12 to 41) 
Hear rate, /min 80 (78 to 86) 
Ejection Fraction, % 60 (56 to 66) 
Blood urea nitrogen ≥ 24mg/dl 23.6 (18.1 to 31.1) 
White cell count, 109/L 6.0 (4.9 to 7.5) 
Triglyceride, mmol/L 1.2 (0.9 to 1.8) 
Magnesium, mmol/L 1.0 (0.9 to 1.1) 
Cardiovascular diseases, n (%) 1,503 (39.9) 
Type 2 Diabetes, n (%) 558 (14.8) 











Table-2. Final multivariate analysis for risk of peritonitis within 6-month of initialisation of peritoneal dialysis 
 
 
Predictor Coefficients 95% Confidence interval 
(age/10)^2 0.2117308 (0.194291 to 0.229171) 
(age/10)^2*ln(age/10) -0.1141053 (-0.122562 to -0.105649) 
(diastolic blood pressure/100)^3 0.3894896 (0.227608 to 0.551372) 
(diastolic blood pressure/100)^3*ln(diastolic blood 
pressure/100) -1.205053 (-1.673582 to -0.736524) 
(Sodium/100)^-2 -1.118932 (-1.645308 to -0.592555) 
(Sodium/100)^-2*ln(Sodium/100) -0.4350019 (-0.637212 to -0.232792) 
Alanine aminotransferase ≥ 15 U/L -0.4272603 (-0.463637 to -0.390883) 
Aspartate transaminase ≥ 17 U/L -0.3352946 (-0.371045 to -0.299544) 
Total protein ≥ 58g/L 0.3829204 (0.349473 to 0.416368) 
Erythrocyte sedimentation rate ≥ 28mm/hr 0.3119003 (0.279601 to 0.344200) 
White cell count ≥ 6×109/L -0.1684228 (-0.201098 to -0.135748) 
Triglyceride ≥ 1.26mmol/L -0.3836425 (-0.418634 to -0.348651) 
Magnesium ≥ 0.98mmol/L 0.4827478 (0.449384 to 0.516111) 
Total cholesterol ≥ 4.43mmol/L -0.0654031 (-0.105478 to -0.025328) 
Fasting glucose ≥ 5.0mmol/L -0.9677222 (-1.004691 to -0.930753) 
Hear rate ≥ 80/min -0.3486695 (-0.384037 to -0.313302) 
Ejection Fraction ≤ 60% -0.3853148 (-0.417759 to -0.352871) 
Blood urea nitrogen ≥ 24mg/dl 0.6670026 (0.633130 to 0.700875) 
Potassium ≥ 4.3mmol/L 0.0730316 (0.039482 to 0.106581) 
Low density lipoprotein ≥ 2.6mmol/L 0.1397471 (0.101377 to 0.178117) 
Systolic blood pressure ≥ 145mmHg 0.0053947 (-0.031752 to 0.042542) 
High density lipoprotein ≤ 1.1mmol/L 0.0336835 (0.000669 to 0.066698) 
carbon dioxide combing power ≥ 22.3mmol/L 0.430856 (0.396910 to 0.464802) 












Table-3. Final multivariate analysis for risk of peritonitis within 6-month of initialisation of peritoneal dialysis   
Measure Apparent performance Optimism corrected performance 
C-statistics 0.761 (0.757 to 0.764) 0.759 (0.756 to 0.762) 













Table-4. Prognostic score chart for predicting early onset peritonitis among patients initialising peritoneal 
dialysis. Clinical example: 76 years old, 60mmHg of diastolic blood pressure, 140.34mmol/L of sodium, 
8.42 U/L of Alanine aminotransferase, 14.50 U/L of Aspartate transaminase, 51.16g/L of total protein, 
8.4*109/L of white cell count, 0.95mmol/L of magnesium, 4.23 mmol/L of total cholesterol, 4.89mmol/L of 
fasting glucose, 70/minute of heart rate, 71.58% of ejection fraction,  20.60mg/dl of blood urea nitrogen, 
5.01 mmol/L of potassium, 1.54 mmol/L of low density lipoprotein, 130 mmHg of systolic blood pressure, 
3.24 mmol/L of high density lipoprotein, and 17.28 mmol/L of carbon dioxide combing power. 
 
 
Predictor Value Score 
(age/10)^2 12.229571 611 
(age/10)^2*ln(age/10) -13.366961 -668 
(diastolic blood pressure/100)^3 0.08412975 4 
(diastolic blood pressure/100)^3*ln(diastolic blood pressure/100) 0.13296354 7 
(Sodium/100)^-2 -0.5681263 -28 
(Sodium/100)^-2*ln(Sodium/100) -0.0748506 -4 
Alanine aminotransferase ≥ 15 U/L 0 0 
Aspartate transaminase ≥ 17 U/L 0 0 
Total protein ≥ 58g/L 0.3829204 19 
Erythrocyte sedimentation rate ≥ 28mm/hr 0.3119003 16 
White cell count ≥ 6*109/L -0.1684228 -8 
Triglyceride ≥ 1.26mmol/L 0 0 
Magnesium ≥ 0.98mmol/L 0 0 
Total cholesterol ≥ 4.43mmol/L 0 0 
Fasting glucose ≥ 5.0mmol/L 0 0 
Hear rate ≥ 80/min 0 0 
Ejection Fraction ≤ 60% 0 0 
Blood urea nitrogen ≥ 24mg/dl 0 0 
Potassium ≥ 4.3mmol/L 0.0730316 4 
Low density lipoprotein ≥ 2.6mmol/L 0 0 
Systolic blood pressure ≥ 145mmHg 0 0 
High density lipoprotein ≤ 1.1mmol/L 0 0 
carbon dioxide combing power ≥ 22.3mmol/L 0 0 
Constant -1.578509 -79 
Sum Score   -127 
Predicted probability for peritonitis   7.29 
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